Stay updated with breaking news from Benevolent Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary...
/PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary...
-- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery...
- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the
IPF is a chronic and ultimately fatal disease that causes lung tissue to stiffen, leading to permanent lung scarring that makes it harder to breathe